- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, ... Read More Read Less
In RRMM, treatment efficacy diminishes with each successive line of therapy
Your treatment choice at first relapse is a pivotal decision with lasting impact for your patients1
Typical Disease Trajectory of Multiple Myeloma: depth and duration of response2,3
Progressive decline in overall response rates (≥PR):
An International Myeloma Foundation study of 383 patients with multiple myeloma who had a documented relapse between January 2007 and June 2010, including 220 from Europe, 106 from Asia, 31 from South America, and 26 from North America, found a decline in response rates over time from 58% at first relapse to 45% at second relapse and 30% at third relapse.4
RRMM = relapsed/refractory multiple myeloma; M-protein = myeloma protein; g/dL = gram per deciliter; 2L = second line; 3L = third line; 4L = fourth line; PR = partial response.
Please see accompanying full Prescribing Information.
Please see accompanying full Prescribing Information.
References: 1. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252-264. 2. Kurtin SE. Relapsed or relapsed/refractory multiple myeloma. J Adv Pract Oncol. 2013;4(suppl 1):5-14. 3. Durie BGM. Concise review of the disease and treatment options: multiple myeloma cancer of the bone marrow. 2018 ed. International Myeloma Foundation website. Accessed September 20, 2022. https://www.myeloma.org/sites/default/files/resource/ConciseReview.pdf. 4. Durie BG, Moreau P, Sonneveld P, et al. Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. J Clin Oncol. 2012;30(15_suppl):8095.